Pfizer, Inc. · NYSE:PFE
Pfizer — Morgan Stanley Global Healthcare Conference 2010
12 slides from Pfizer's conference presentation, Sep 13, 2010
Slide 1: Pfizer Worldwide Research & Development
Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010
Slide 2: Forward-Looking Statements
Forward-Looking Statements Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2009 Annual Repo
Slide 3: A Revitalized R&D Organization
Pfizer Worldwide Research & Development A Revitalized R&D Organization PGRD + BBC + Wyeth R&D Centered on pipeline delivery Improving decision-making and clinical development of candidates BioTx + PharmaTx Delivering smarter and more authentic integration of science and business Applying a b
Slide 4: Delivering the Benefits of Integration
Delivering the Benefits of Integration WRD Scientific Leadership Team Four core R&D Groups Chief Scientific Officers lead 20 Research and Mikael Dolsten Jose-Carlos Rod MacKenzie Emilio Emini Rodney Lappe Jaume Pons Biotechnology Units Worldwide R&D Gutierrez-Ramos PTx R&D Vaccine R&D Biotech Un
Slide 5: Our Operating Model Drives Strong Alignment Between R&D and Commercial BUs
Our Operating Model Drives Strong Alignment Between R&D and Commercial BUs Worldwide R&D Business Units IND FIH PoC Pre- Reg / Discovery Ph 1 Ph 2 Ph 3 Clinical Launch Ongoing dialog with BUs on key product Agreed PoC attributes and criteria decision • Rationale & key data analyses tools • Positioni
Slide 6: Pfizer WRD: Meeting the Challenges - Focused on Three Horizons
Pfizer WRD: Meeting the Challenges Focused on Three Horizons Horizon 3 R&D Ecosystem of the Future To Drive Sustained Progress • Precision Medicine • Networked, interactive R&D • Breakthrough productivity Horizon 2 Innovate New Capabilities • Next generation therapeutics • Open and external innovati
Slide 7: Our Portfolio is Supported by Leading Drug Design Capabilities
Our Portfolio is Supported by Leading Drug Design Capabilities (e.g., Biologics) Pfizer leads in cutting-edge ... And is pursuing technologies of technology platforms ... the future Vaccines Inflammation / Immunology Shark IgNARs CovX Bodies Peptides ADCs Oncology Bifunct Neuroscience / Pain CovX Ta
Slide 8: A Dual-Acting Anti-Angiogenic CovX-Body Designed for Improved Treatment of Cancers
A Dual-Acting Anti-Angiogenic CovX-Body Designed for Improved Treatment of Cancers A Bi-functional CovX-Body Inhibition of tumor growth with two targets in an animal model by CovX-Body Angiopoietin-2 (Ang-2) Decreased Tumor vollume mm 3 tumor 2000 volume Vascular endothelial 1000 growth factor ligan
Slide 9: Targeting Lung Cancer Treatments in Patient Subsets to Improve Outcomes
Targeting Lung Cancer Treatments in Patient Subsets to Improve Outcomes Crizotinib: A potent and ... initially being developed selective oral inhibitor of for MET mechanism MET and ALK Academic discovery of new patient segment redefined lung cancer 10 15%1 of non small cell lung cancer 10-15% (NSCLC
Slide 10: Clinical Outcome for NSCLC Patients After Crizotinib Treatment
Clinical Outcome for NSCLC Patients After Crizotinib Treatment 9 Note: Patients in trial composed of 2nd to 4th line. 1st line response to Standard of Care: ~50%, 2nd line: ~10%, 3rd line: 3-5%
Slide 11: Exciting Drug Programs Progressing Toward Proof of Concept
Exciting Drug Programs Progressing Toward Proof of Concept • Growing diabetes portfolio with Long Acting GLP-1 CovX body, OAP peptide drugs and SGLT2 drugs (Ph 1-2) – Powerful glucose control, favorable body weight effects and attractive tolerability profile • First evidence of clinical differentiat
Slide 12: Key Late-Phase Portfolio Candidates
Key Late-Phase Portfolio Candidates In Registration Celebrex Chronic Pain Lyrica GAD (monotherapy) Sutent Pancreatic neuroendocrine tumors Pristiq Vasomotor Symptoms of Menopause Viviant Osteoporosis Treatment and Prevention Xiapex Dupuytren's Contracture (MAA) apixaban VTE prevention (MAA) Taligluc
Pfizer — Morgan Stanley Global Healthcare Conference 2010 on 6ix